Loading stock data…
JBIO
$24.23-0.17 (-0.70%)
Market ClosedLast close May 1
Jade Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jade Biosciences, Inc. in the Healthcare sector is trading at $24.23. The stock is currently near its 52-week high of $28.00, remaining 92.9% above its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why JBIO maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.23
Potential Upside
5%
Whystock Fair Value$25.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Induci...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
9.91%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.32%
Volume
Today's trading volume
613,227
Recent News
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
Jade Biosciences (NASDAQ:JBIO) outlined its strategy and near-term milestones at the Oppenheimer Life Sciences Conference, where CEO Tom Frohlich described the company’s focus on developing “best-in-class” monoclonal antibodies for autoimmune diseases using high-affinity binding and half-life extens
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically […]
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week
Key Insights Institutions' substantial holdings in Jade Biosciences implies that they have significant influence over...
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target. In an investor note, the analyst underlined that there was conviction in JADE101, which […]